Ardelyx's first approved product, IBSRELA (tenapanor) is available in the United States and Canada. The US company is also developing XPHOZAH (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase III trials.

The company has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.